|
A
day in the life of a vaccine
educator
Central to the success of the testing of an HIV/ AIDS vaccine are the
vaccine educators. IZELLE THEUNISSEN spoke to the three vaccine educators
located at the MRC.
The SAAVI vaccine educators are Petronella Goliath (standing, right),
Laurentia Ogle and Tshilidzi Tuwane (sitting).
The vaccine educators
do exactly what their title says: they go out into the community and
educate people about what a vaccine is, what it's
going to do and how it's going to affect them.
This takes a special
kind of individual, and this is exactly what I found when I interviewed
Petronella Goliath, Laurentia Ogle and Tshilidzi Tuwane.
You can't
imagine three people more different. Coming from different parts
of the country and each having their own educational background, they have
one thing in common: a passion for people.
Laurentia didn't even
know what a vaccine was when she came to the MRC, but she found that her
previous job experience and qualifications (she was a receptionist
at a private hospital and then a community relations consultant for a telecommunications
company) helped her interact with sometimes skeptical communities.
It's quite a challenge
communicating a highly technical innovation to people with mostly no scientific
background. Tshilidzi says: "The most
difficult part of my job is to explain
scientific terms such as placebo-controlled research to the community
in a language they can understand. The comic books, training manuals and
brochures produced by SAAVI help a lot because they are written in simple
English."
Petronella finds
that people generally know something about vaccines, but HIV vaccines
are a new concept. "I always start my explanation
by using something they are familiar with, such as the vaccines they received
as chilren.
We then build on that
knowledge through group discussions, working step-by-step and allowing
feedback and input," she explains.
The educators
agree that they are always warmly received, although Tshilidzi says that
he is very often asked whether the community was going to be used as guineapigs.
"But people are tired of seeing the consequences of AIDS in their communities
and they want to do something," he says.
Laurentia says she has
heard communities say that they are tired of
hearing the basics about HIV/ AIDS - they want to hear something
new. She also raises an interesting issue. "Many communities are concerned
that the scientists are wasting money, time and energy since this is a preventative
vaccine which will benefit HIV negative people only."
However, people
seem to appreciate that the educators are communicating with them about
the vaccine research. "They often ask what the other research organizations
are doing and why their research is not communicated," says Laurentia.
How do the educators
get into the communities? "My first introduction will be through HIV/ AIDS
organizations that are already involved in the community. I start by asking
for a platform to introduce our organization and explain our aims. This
will be followed by a request to build a working relationship. An action
plan will then be developed," explains Petronella.
Laurentia says being
placed at one of the trial sites (in Durban) is an advantage for her.
"I have worked closely with the trial site staff, and in this way I have
learnt a lot in a short time. I also arrange seminars for target groups
where I call on the scientists to come and explain certain topics," she
says.
The educators all agree
that men don't attend
the seminars and that this is quite a challenge. "If the community
requests a seminar, you'll find that 99% of attendees are female.
When I initiate a seminar or workshop, I always ask for equal representation,
but this never happens," says Laurentia.
The educators all
love their job. Laurentia says she loves being exposed to both worlds:
the scientific and the community. Adds Petronella: "I enjoy
educating the scientists about the community. Also the participation
of the community and their
appreciation for our programme."
Tshilidzi
is philosophical: "The
HIV/ Aids vaccine is an innovation that is aimed at solving the biggest problem
the world has ever faced. I like being involved with the people coming up
with a strategy to solve the problem - especially here in South Africa,
where I was born."
What
the communities have asked the vaccine educators:
- Do you want
to infect all of us by injecting us with the virus?
- Who are the
scientists in South Africa and how can they be sure of finding a vaccine
when the guys in America couldn't find one?
- Why don't
you test the vaccine on prisoners?
- Why don't
you test the vaccine on unconscious people who are going to die anyway?
MICHELLE
GALLOWAY from SAAVI tells MRC News why vaccine educators are so
important to the trials.

From the
start of the initiative the importance of educating and mobilizing
communities has been seen as vitally important. We simply won't be
able to run successful trials without educated individuals and communities
that are in a position to make informed decisions about participation.
With this
in mind, SAAVI started an extensive project (funded by SAAVI and
the European Union) to raise awareness, educate and mobilize activities
within communities, with a specific emphasis on human rights. This
was initially known as the South African HIV Vaccine Action Campaign
(SA HIVAC) and more recently the SAAVI Community Preparedness Programme.
The vaccine
educators are the heart and soul of this programme. They use workshops
to target identified change agents within communities (including
non-governmental and AIDS service organizations already undertaking
general AIDS education activities) and educate them to spread the
message about HIV vaccines and about the scientific and clinical
processes involved in developing vaccines as widely as possible among
the broader communities - specifically those around the trial sites. |
Update
on the vaccine trials
The
past year has seen the commencement of two phase I clinical trials at
two trial sites in South Africa. This step catapulted South Africa to
the forefront of vaccine development as the first country to test a C
clade vaccine and the first African country to be running multiple clinical
trials. The two trials commenced within a week of each other in November
at the Soweto and Durban trial sites.
The two
vaccines - the VEE clade C candidate and the MVA clade A candidate
- represent considerable international collaborative efforts involving
many international partners.
The VEE
(Venezuelan Equine Encephalitis) candidate was developed by researchers
from the Universities of Cape Town and North Carolina, manufactured
by AlphaVax, and the trial is being run by the HIV Vaccine Trials
Network of the US National Institutes of Health with volunteers in
both South Africa and
the USA.
The MVA
(Modified Vaccinia Ankara) candidate was developed by researchers
of the Universitites of Oxford and Kenya and sponsored by the International
AIDS Vaccine Initiative. This has already been tested in Kenya and
the UK.
A third
trial is pending approval and could start during 2004. Also, some
of the wholly South African developed test vaccines are in the early
regulatory and manufacturing stages and could also be approved for
trials in the not-too-distant future.
All of
these trials will feed not only into local knowledge and development,
but also substantially into international efforts to find a successful
HIV/ Aids vaccine. Because of the many as yet unanswered questions
in vaccine development and the urgency of the need for an effective
vaccine, running simultaneous multiple phase I trials is essential. |
|